Open AccessIndividualized treatment of breast cancer with chronic renal failure: A case report and review of literature
Author(s) -
Jiehui Cai,
Jiehua Zheng,
Xiaoqi Lin,
Weixun Lin,
Juan Zou,
Yao-Kun Chen,
Zhiyang Li,
Chen Ye-xi
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i33.10345
Subject(s) - medicine , pertuzumab , trastuzumab , breast cancer , docetaxel , regimen , oncology , cancer , neoadjuvant therapy , contraindication , surgery , urology , pathology , alternative medicine
Studies have shown that patients with chronic renal failure (CRF) are more likely to suffer from breast cancer and other malignant tumors. To our knowledge, CRF can reduce drug excretion, thereby increase drug exposure and lead to increased toxicity, which will limit drug treatment and lead to tumor progression. Currently, there are few successful reports on the combination of docetaxel, trastuzumab, and pertuzumab (THP) as a neoadjuvant treatment regimen for breast cancer patients with CRF.